Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.

@article{Fliser2005AsymmetricDA,
  title={Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.},
  author={Danilo Fliser and Florian Kronenberg and Jan T Kielstein and Christian Morath and Stefanie Margarethe Bode-B{\"o}ger and Hermann W. Haller and Elizabeth Ritz},
  journal={Journal of the American Society of Nephrology : JASN},
  year={2005},
  volume={16 8},
  pages={
          2456-61
        }
}
Reduced bioavailability of nitric oxide (NO) is thought to play an important role in progression of renal damage. The hypothesis that the endogenous NO synthase inhibitor asymmetric dimethylarginine (ADMA) is involved in progression of kidney disease was tested. Plasma ADMA concentrations and other putative progression factors were assessed in 227 relatively young patients (45.7 +/- 12.6 yr) with nondiabetic kidney diseases and mild to moderate renal failure. Progression assessed as doubling of… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 169 CITATIONS

FILTER CITATIONS BY YEAR

2005
2019

CITATION STATISTICS

  • 10 Highly Influenced Citations

  • Averaged 9 Citations per year over the last 3 years

Similar Papers

Loading similar papers…